Pulmonary hypertension in the developing world: Local registries, challenges, and ways to move forward.

Pulmonary hypertension (PH) is a disease that can only be appropriately managed  in the ‘rich’ developed countries, as both diagnostic and therapeutic interventions are extremely expensive and expectations for these to be adopted by the developing, economically-challenged countries are neither practical nor realistic. Furthermore, most of the enormous advances in understanding the pathobiology of PH and the subsequent evidence-based diagnostic and complex treatment algorithms came from the developed world.